Nature Communications (Sep 2021)
Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma
- Guangxi Sun,
- Junru Chen,
- Jiayu Liang,
- Xiaoxue Yin,
- Mengni Zhang,
- Jin Yao,
- Ning He,
- Cameron M. Armstrong,
- Linmao Zheng,
- Xingming Zhang,
- Sha Zhu,
- Xiaomeng Sun,
- Xiaoxia Yang,
- Wanbin Zhao,
- Banghua Liao,
- Xiuyi Pan,
- Ling Nie,
- Ling Yang,
- Yuntian Chen,
- Jinge Zhao,
- Haoran Zhang,
- Jindong Dai,
- Yali Shen,
- Jiyan Liu,
- Rui Huang,
- Jiandong Liu,
- Zhipeng Wang,
- Yuchao Ni,
- Qiang Wei,
- Xiang Li,
- Qiao Zhou,
- Haojie Huang,
- Zhenhua Liu,
- Pengfei Shen,
- Ni Chen,
- Hao Zeng
Affiliations
- Guangxi Sun
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University
- Junru Chen
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University
- Jiayu Liang
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University
- Xiaoxue Yin
- Department of Pathology, West China Hospital, Sichuan University
- Mengni Zhang
- Department of Pathology, West China Hospital, Sichuan University
- Jin Yao
- Department of Radiology, West China Hospital, Sichuan University
- Ning He
- GloriousMed Clinical Laboratory (Shanghai) Co., Ltd
- Cameron M. Armstrong
- Department of Urology and Comprehensive Cancer Center, University of California Davis
- Linmao Zheng
- Department of Pathology, West China Hospital, Sichuan University
- Xingming Zhang
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University
- Sha Zhu
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University
- Xiaomeng Sun
- GloriousMed Clinical Laboratory (Shanghai) Co., Ltd
- Xiaoxia Yang
- GloriousMed Clinical Laboratory (Shanghai) Co., Ltd
- Wanbin Zhao
- GloriousMed Clinical Laboratory (Shanghai) Co., Ltd
- Banghua Liao
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University
- Xiuyi Pan
- Department of Pathology, West China Hospital, Sichuan University
- Ling Nie
- Department of Pathology, West China Hospital, Sichuan University
- Ling Yang
- Department of Radiology, West China Hospital, Sichuan University
- Yuntian Chen
- Department of Radiology, West China Hospital, Sichuan University
- Jinge Zhao
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University
- Haoran Zhang
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University
- Jindong Dai
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University
- Yali Shen
- Department of Oncology, West China Hospital, Sichuan University
- Jiyan Liu
- Department of Biotherapy, West China Hospital, Sichuan University
- Rui Huang
- Department of Nuclear medicine, West China Hospital, Sichuan University
- Jiandong Liu
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University
- Zhipeng Wang
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University
- Yuchao Ni
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University
- Qiang Wei
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University
- Xiang Li
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University
- Qiao Zhou
- Department of Pathology, West China Hospital, Sichuan University
- Haojie Huang
- Departments of Biochemistry and Molecular Biology and Urology, Mayo Clinic College of Medicine and Science
- Zhenhua Liu
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University
- Pengfei Shen
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University
- Ni Chen
- Department of Pathology, West China Hospital, Sichuan University
- Hao Zeng
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University
- DOI
- https://doi.org/10.1038/s41467-021-25618-z
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 13
Abstract
TFE3-translocation renal cell carcinoma (TFE3-tRCC) is a rare subtype of kidney cancer with no standard treatment options for the advanced disease. Here, the authors perform genomic and transcriptomic profiling of 63 untreated primary TFE3-tRCC tumours and reveal potential therapeutic targets.
